This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 Jul 2011

Levomilnacipran Found Effective against Major Depressive Disorder

The study demonstrated the safety and tolerability of Levomilnacipran in patients with major depressive disorder.

Forest Laboratories and its partner Pierre Fabre Medicament have released the preliminary top-line results from a Phase III study of once-daily Levomilnacipran as a treatment for major depressive disorder in adults.


Levomilnacipran (1S,2R-milnacipran) is a potent and selective inhibitor of the reuptake of norepinephrine and serotonin, which are known to regulate mood.


The randomised, double-blind, placebo-controlled and fixed-dose study, which involved 724 patients, showed a mean change from baseline to end of week eight in the Montgomery-Asberg Depression Rating Scale-Clinician Rated total score.


The study also demonstrated the safety and tolerability of Levomil

Related News